Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases

Paolo Magni, Chiara MacChi, Cesare R. Sirtori, Massimiliano Marco Corsi Romanelli

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Clear evidence supports a role for circulating and locally-produced osteocalcin (OC) in the pathophysiology of cardiovascular (CV) lesions and CV risk, also in combination with metabolic changes, including type 2 diabetes mellitus (T2DM). Reduced plasma OC levels are associated with greater incidence of pathological CV changes, like arterial and valvular calcification, coronary and carotid atherosclerosis and increased carotid intima-media thickness. The actual relationship between OC levels and incidence of major CV events is, however, still unclear. Moreover, reduced circulating OC levels have been mostly associated with insulin resistance, metabolic syndrome or T2DM, indicating relevant OC actions on pancreatic β-cells and insulin secretion and activity. Based on these observations, this review article will attempt to summarize the current evidence on the potential usefulness of circulating OC as a biomarker for CV and metabolic risk, also evaluating the currently open issues in this area of research.

Original languageEnglish
Pages (from-to)1579-1587
Number of pages9
JournalClinical Chemistry and Laboratory Medicine
Volume54
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Osteocalcin
Metabolic Diseases
Biomarkers
Cardiovascular Diseases
Medical problems
Type 2 Diabetes Mellitus
Insulin
Carotid Intima-Media Thickness
Carotid Artery Diseases
Incidence
Insulin Resistance
Coronary Artery Disease
Plasmas
Research

Keywords

  • Atherosclerosis
  • Cardiovascular risk
  • Metabolic syndrome
  • Osteocalcin
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases. / Magni, Paolo; MacChi, Chiara; Sirtori, Cesare R.; Corsi Romanelli, Massimiliano Marco.

In: Clinical Chemistry and Laboratory Medicine, Vol. 54, No. 10, 01.10.2016, p. 1579-1587.

Research output: Contribution to journalReview article

@article{5f5f15a841a54759bfbb011930619291,
title = "Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases",
abstract = "Clear evidence supports a role for circulating and locally-produced osteocalcin (OC) in the pathophysiology of cardiovascular (CV) lesions and CV risk, also in combination with metabolic changes, including type 2 diabetes mellitus (T2DM). Reduced plasma OC levels are associated with greater incidence of pathological CV changes, like arterial and valvular calcification, coronary and carotid atherosclerosis and increased carotid intima-media thickness. The actual relationship between OC levels and incidence of major CV events is, however, still unclear. Moreover, reduced circulating OC levels have been mostly associated with insulin resistance, metabolic syndrome or T2DM, indicating relevant OC actions on pancreatic β-cells and insulin secretion and activity. Based on these observations, this review article will attempt to summarize the current evidence on the potential usefulness of circulating OC as a biomarker for CV and metabolic risk, also evaluating the currently open issues in this area of research.",
keywords = "Atherosclerosis, Cardiovascular risk, Metabolic syndrome, Osteocalcin, Type 2 diabetes mellitus",
author = "Paolo Magni and Chiara MacChi and Sirtori, {Cesare R.} and {Corsi Romanelli}, {Massimiliano Marco}",
year = "2016",
month = "10",
day = "1",
doi = "10.1515/cclm-2015-0953",
language = "English",
volume = "54",
pages = "1579--1587",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "10",

}

TY - JOUR

T1 - Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases

AU - Magni, Paolo

AU - MacChi, Chiara

AU - Sirtori, Cesare R.

AU - Corsi Romanelli, Massimiliano Marco

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Clear evidence supports a role for circulating and locally-produced osteocalcin (OC) in the pathophysiology of cardiovascular (CV) lesions and CV risk, also in combination with metabolic changes, including type 2 diabetes mellitus (T2DM). Reduced plasma OC levels are associated with greater incidence of pathological CV changes, like arterial and valvular calcification, coronary and carotid atherosclerosis and increased carotid intima-media thickness. The actual relationship between OC levels and incidence of major CV events is, however, still unclear. Moreover, reduced circulating OC levels have been mostly associated with insulin resistance, metabolic syndrome or T2DM, indicating relevant OC actions on pancreatic β-cells and insulin secretion and activity. Based on these observations, this review article will attempt to summarize the current evidence on the potential usefulness of circulating OC as a biomarker for CV and metabolic risk, also evaluating the currently open issues in this area of research.

AB - Clear evidence supports a role for circulating and locally-produced osteocalcin (OC) in the pathophysiology of cardiovascular (CV) lesions and CV risk, also in combination with metabolic changes, including type 2 diabetes mellitus (T2DM). Reduced plasma OC levels are associated with greater incidence of pathological CV changes, like arterial and valvular calcification, coronary and carotid atherosclerosis and increased carotid intima-media thickness. The actual relationship between OC levels and incidence of major CV events is, however, still unclear. Moreover, reduced circulating OC levels have been mostly associated with insulin resistance, metabolic syndrome or T2DM, indicating relevant OC actions on pancreatic β-cells and insulin secretion and activity. Based on these observations, this review article will attempt to summarize the current evidence on the potential usefulness of circulating OC as a biomarker for CV and metabolic risk, also evaluating the currently open issues in this area of research.

KW - Atherosclerosis

KW - Cardiovascular risk

KW - Metabolic syndrome

KW - Osteocalcin

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84987700853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987700853&partnerID=8YFLogxK

U2 - 10.1515/cclm-2015-0953

DO - 10.1515/cclm-2015-0953

M3 - Review article

AN - SCOPUS:84987700853

VL - 54

SP - 1579

EP - 1587

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 10

ER -